Mark R Middleton Selected Research

Mark R Middleton Research Topics

Disease

54	Melanoma (Melanoma, Malignant) 05/2022 - 08/2002
51	Neoplasms (Cancer) 01/2022 - 01/2003
13	Neoplasm Metastasis (Metastasis) 01/2022 - 05/2014
6	Disease Progression 12/2019 - 06/2007
5	Brain Neoplasms (Brain Tumor) 01/2022 - 10/2015
5	Adenocarcinoma 01/2020 - 07/2012
4	Fatigue 01/2020 - 01/2003
4	Diarrhea 01/2019 - 01/2003
3	Pancreatic Neoplasms (Pancreatic Cancer) 04/2021 - 07/2012
3	Drug-Related Side Effects and Adverse Reactions 11/2020 - 05/2014
3	Vomiting 01/2020 - 07/2013
3	Exanthema (Rash) 01/2020 - 07/2012
3	Hyperthermia 01/2019 - 01/2017
3	Breast Neoplasms (Breast Cancer) 01/2019 - 01/2018
3	Colorectal Neoplasms (Colorectal Cancer) 12/2018 - 01/2010
3	Neutropenia 01/2018 - 07/2013
2	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 01/2010
2	Colitis 10/2021 - 11/2020
2	Lymphoma (Lymphomas) 07/2021 - 01/2019
2	Stomach Neoplasms (Stomach Cancer) 01/2020 - 05/2019
2	Esophageal Neoplasms (Esophageal Cancer) 12/2019 - 02/2017
2	Barrett Esophagus (Barrett's Esophagus) 07/2016 - 01/2016
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2016 - 08/2014
2	Prostatic Neoplasms (Prostate Cancer) 10/2014 - 01/2010
1	Inflammation (Inflammations) 01/2022
1	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2021
1	Uveal melanoma 11/2020
1	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 11/2020
1	Pneumonia (Pneumonitis) 11/2020
1	Liver Diseases (Liver Disease) 10/2019
1	Hepatitis 10/2019
1	Cholangitis 10/2019

Drug/Important Bio-Agent (IBA)

15	IpilimumabIBA 05/2022 - 01/2012
10	Pharmaceutical PreparationsIBA 10/2019 - 01/2012
9	Immune Checkpoint InhibitorsIBA 05/2022 - 01/2016
9	Proteins (Proteins, Gene)FDA Link 07/2021 - 05/2005
9	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 06/2004
8	NivolumabIBA 05/2022 - 11/2017
8	Biomarkers (Surrogate Marker)IBA 10/2021 - 03/2014
7	Temozolomide (Temodar)FDA LinkGeneric 11/2015 - 08/2002
6	VemurafenibIBA 01/2017 - 01/2012
5	dabrafenibIBA 01/2021 - 05/2013
5	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2015 - 07/2012
4	pembrolizumabIBA 05/2022 - 11/2017
4	InterferonsIBA 01/2021 - 11/2010
3	RNA (Ribonucleic Acid)IBA 10/2021 - 01/2021
3	trametinibIBA 01/2021 - 07/2012
3	Bevacizumab (Avastin)FDA Link 11/2020 - 05/2014
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020 - 09/2012
3	Gemcitabine FDA Link 01/2014 - 08/2003
3	lomeguatribIBA 01/2010 - 03/2006
2	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2022 - 01/2019
2	AntigensIBA 11/2021 - 11/2020
2	Histone Deacetylase InhibitorsIBA 07/2021 - 01/2019
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2020 - 05/2014
2	AntibodiesIBA 11/2020 - 10/2014
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 12/2019 - 05/2019
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2019 - 01/2018
2	talimogene laherparepvecIBA 01/2019 - 09/2015
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2019 - 09/2015
2	Estrogen ReceptorsIBA 01/2019 - 01/2018
2	AlpelisibIBA 01/2019 - 01/2018
2	ErbB Receptors (EGF Receptor)IBA 01/2018 - 01/2016
2	rucaparibIBA 03/2017 - 05/2013
2	Carboplatin (JM8)FDA LinkGeneric 03/2017 - 08/2003
2	Cyclin B1IBA 11/2016 - 05/2013
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2016 - 09/2015
2	CH 4987655IBA 08/2014 - 09/2012
2	Dacarbazine (DIC)FDA LinkGeneric 07/2013 - 01/2003
2	MethyltransferasesIBA 12/2011 - 06/2007
2	Alkylating AgentsIBA 08/2006 - 01/2003
1	Gadolinium DTPA (Magnevist)FDA Link 01/2022
1	Janus Kinase InhibitorsIBA 10/2021
1	tofacitinibIBA 10/2021
1	Interferon-gamma (Interferon, gamma)IBA 10/2021
1	AcetylesteraseIBA 07/2021
1	Histones (Histone)IBA 07/2021
1	VX (EDIM)IBA 01/2021
1	A 121IBA 01/2021
1	Protein Kinases (Protein Kinase)IBA 01/2021
1	berzosertibIBA 01/2021
1	tebentafuspIBA 11/2020
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 11/2020
1	CytokinesIBA 11/2020
1	cyclopropapyrroloindoleIBA 01/2020
1	AZD 8931IBA 01/2020
1	XELOXIBA 01/2020
1	Capecitabine (Xeloda)FDA Link 01/2020
1	Alanine Transaminase (SGPT)IBA 10/2019
1	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2019
1	Programmed Cell Death 1 ReceptorIBA 10/2019
1	SteroidsIBA 10/2019
1	Infliximab (Remicade)FDA Link 10/2019

Therapy/Procedure

29	Therapeutics 05/2022 - 12/2005
15	Drug Therapy (Chemotherapy) 01/2020 - 06/2004
5	Immunotherapy 11/2021 - 09/2015
5	Radiotherapy 11/2019 - 09/2012
4	Neoadjuvant Therapy 12/2019 - 10/2016
2	Adjuvant Chemotherapy 02/2014 - 07/2012
1	Intravenous Administration 01/2022